The Definition of HIV-associated Neurocognitive Disorders: Are We Overestimating the Real Prevalence?

Overview

Journal BMC Infect Dis

Publisher Biomed Central

Specialty Infectious Diseases

Date 2011 Dec 30

PMID 22204557

Citations 119

Authors

Magnus Gisslen

Richard W Price

Staffan Nilsson

Affiliations

Soon will be listed here.

Abstract

Background: A substantial prevalence of mild neurocognitive disorders has been reported in HIV, also in patients treated with combination antiretroviral therapy (cART). This includes a new disorder that has been termed asymptomatic neurocognitive impairment (ANI).

Discussion: ANI is identified by performance on formal neuropsychological testing that is at least 1 SD below the mean of normative scores in at least two cognitive domains out of at least five examined in patients without associated symptoms or evident functional impairment in daily living. While two tests are recommended to assess each domain, only one is required to fulfill this diagnostic criterion. Unfortunately, this definition necessitates that about 20% of the cognitively normal HIV-infected population is classified as suffering ANI. This liberal definition raises important ethical concerns and has as well diagnostic and therapeutic implications. Since neither its biological substrate, prognostic significance nor therapeutic implications are clearly established, we recommend that this diagnosis be modified or applied cautiously.

Summary: The diagnoses of less severe forms of neurocognitive disorders in HIV relies on the outcomes of neuropsychological testing, and a high proportion of HIV-infected patients with effective cART may be classified as neurocognitively abnormal using the current criteria. The definition of ANI is not stringent, and results in approximately 20% of the population being classified as abnormal. To us this seems an unacceptable false-positive rate.

Citing Articles

Advances in assessment and cognitive neurorehabilitation of HIV-related neurocognitive impairment.

Fischer E, Renaud A, Grivaz P, Di Liberto G, Ryvlin P, Cavassini M Brain Commun. 2024; 7(1):fcae399.

PMID: 39726816 PMC: 11670355. DOI: 10.1093/braincomms/fcae399.

Psychosocial factors account for a proportion of the difference in cognitive performance between persons with and without HIV.

Dreyer A, Le Roux C, Gf Thomas K, Thomas K, Sabin C, Winston A AIDS. 2024; 39(4):393-402.

PMID: 39621015 PMC: 11872261. DOI: 10.1097/QAD.0000000000004080.

The magnitude of neurocognitive disorders and associated factors among people living with HIV AIDS facilities in Bahir Dar City Ethiopia.

Manaye M, Melese E, Wassie G Sci Rep. 2024; 14(1):19058.

PMID: 39154066 PMC: 11330510. DOI: 10.1038/s41598-024-68909-3.

Medical comorbidities and lower myelin content are associated with poor cognition in young adults with perinatally acquired HIV.

Patel P, Prince D, Bolenzius J, Chen P, Chiarella J, Kolind S AIDS. 2024; 38(14):1932-1939.

PMID: 39110577 PMC: 11524773. DOI: 10.1097/QAD.0000000000003989.

Self-reported neurocognitive complaints in the Swiss HIV Cohort Study: a viral genome-wide association study.

Zeeb M, Pasin C, Cavassini M, Bieler-Aeschlimann M, Frischknecht P, Kusejko K Brain Commun. 2024; 6(4):fcae188.

PMID: 38961872 PMC: 11220509. DOI: 10.1093/braincomms/fcae188.

References

Lescure F, Omland L, Engsig F, Roed C, Gerstoft J, Pialoux G . Incidence and impact on mortality of severe neurocognitive disorders in persons with and without HIV infection: a Danish nationwide cohort study. Clin Infect Dis. 2011; 52(2):235-43. DOI: 10.1093/cid/ciq041. View

Petersen R . Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004; 256(3):183-94. DOI: 10.1111/j.1365-2796.2004.01388.x. View

Pumpradit W, Ananworanich J, Lolak S, Shikuma C, Paul R, Siangphoe U . Neurocognitive impairment and psychiatric comorbidity in well-controlled human immunodeficiency virus-infected Thais from the 2NN Cohort Study. J Neurovirol. 2010; 16(1):76-82. DOI: 10.3109/13550280903493914. View

Antinori A, Arendt G, Becker J, Brew B, Byrd D, Cherner M . Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007; 69(18):1789-99. PMC: 4472366. DOI: 10.1212/01.WNL.0000287431.88658.8b. View

Gisslen M, Hagberg L, Rosengren L, Brew B, Cinque P, Spudich S . Defining and evaluating HIV-related neurodegenerative disease and its treatment targets: a combinatorial approach to use of cerebrospinal fluid molecular biomarkers. J Neuroimmune Pharmacol. 2007; 2(1):112-9. DOI: 10.1007/s11481-006-9035-1. View

Simioni S, Cavassini M, Annoni J, Rimbault Abraham A, Bourquin I, Schiffer V . Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS. 2009; 24(9):1243-50. DOI: 10.1097/QAD.0b013e3283354a7b. View

Heaton R, Clifford D, Franklin Jr D, Woods S, Ake C, Vaida F . HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology. 2010; 75(23):2087-96. PMC: 2995535. DOI: 10.1212/WNL.0b013e318200d727. View

Cysique L, Brew B . Prevalence of non-confounded HIV-associated neurocognitive impairment in the context of plasma HIV RNA suppression. J Neurovirol. 2011; 17(2):176-83. DOI: 10.1007/s13365-011-0021-x. View

McKhann G, Knopman D, Chertkow H, Hyman B, Jack Jr C, Kawas C . The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7(3):263-9. PMC: 3312024. DOI: 10.1016/j.jalz.2011.03.005. View

10.

Canestri A, Lescure F, Jaureguiberry S, Moulignier A, Amiel C, Marcelin A . Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis. 2010; 50(5):773-8. DOI: 10.1086/650538. View

11.

Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M . CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA. 2009; 302(4):385-93. DOI: 10.1001/jama.2009.1064. View

12.

Bhaskaran K, Mussini C, Antinori A, Walker A, Dorrucci M, Sabin C . Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy. Ann Neurol. 2007; 63(2):213-21. DOI: 10.1002/ana.21225. View

13.

Monforte A, Cinque P, Mocroft A, Goebel F, Antunes F, Katlama C . Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol. 2004; 55(3):320-8. DOI: 10.1002/ana.10827. View

14.

Munoz-Moreno J, Fumaz C, Ferrer M, Prats A, Negredo E, Garolera M . Nadir CD4 cell count predicts neurocognitive impairment in HIV-infected patients. AIDS Res Hum Retroviruses. 2008; 24(10):1301-7. DOI: 10.1089/aid.2007.0310. View

15.

Robertson K, Smurzynski M, Parsons T, Wu K, Bosch R, Wu J . The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS. 2007; 21(14):1915-21. DOI: 10.1097/QAD.0b013e32828e4e27. View